NCT02808364View on ClinicalTrials.gov

Personalized Cellular Vaccine for Recurrent Glioblastoma (PERCELLVAC2)

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 1, 2016

Primary Completion Date

October 31, 2017

Study Completion Date

June 30, 2019

Conditions
Glioblastoma
Interventions
BIOLOGICAL

Personalized cellular vaccine

Patients with recurrent glioblastoma will undergo tumor resection and receive tumor antigen pulsed cellular vaccines.

Trial Locations (1)

Unknown

Guangdong 999 Brain Hospital, Guangzhou

Sponsors
All Listed Sponsors
collaborator

Beijing Tricision Biotherapeutics Inc

INDUSTRY

collaborator

Zhuhai Trinomab Pharmaceutical Co., Ltd.

INDUSTRY

collaborator

Jinan University Guangzhou

OTHER

lead

Guangdong 999 Brain Hospital

OTHER

NCT02808364 - Personalized Cellular Vaccine for Recurrent Glioblastoma (PERCELLVAC2) | Biotech Hunter | Biotech Hunter